Publikationen

Chenel M, Dallmann A, Ince I, Meyer M, Schlender JF, Teutonico D, Sjögren E. Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling. CPT Pharmacometrics Syst Pharmacol. 2026 Jul;15(7):e70295. doi: 10.1002/psp4.70295. Review. PubMed PMID: 42400597; PubMed Central PMCID: PMC13332702.select
Vrenken P, Vertzoni M, Frechen S, Solodenko J, Meyer M, Muenster U, Dallmann A. Development of a novel physiologically based biopharmaceutics modeling (PBBM) framework using the open systems pharmacology suite, part 2: in vivo pharmacokinetic modeling of vericiguat. Eur J Pharm Sci. 2025 Sep 1;212:107189. doi: 10.1016/j.ejps.2025.107189. Epub 2025 Jul 2. PubMed PMID: 40615096.select
Vrenken P, Vertzoni M, Frechen S, Solodenko J, Meyer M, Muenster U, Dallmann A. Development of a novel physiologically based biopharmaceutics modeling (PBBM) framework using the open systems pharmacology suite, part 1: in vitro modeling of vericiguat. Eur J Pharm Sci. 2025 Sep 1;212:107164. doi: 10.1016/j.ejps.2025.107164. Epub 2025 Jun 10. PubMed PMID: 40505839.select
Fudim M, Khan MS, Linz D, Lindenfeld J, MacRae C, Kimmeskamp-Kirschbaum N, Meyer M, Mondritzki T, Tinel H, Dinh W, Mentz RJ. Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study. Sci Rep. 2024 Dec 30;14(1):31585. doi: 10.1038/s41598-024-77111-4. PubMed PMID: 39738130; PubMed Central PMCID: PMC11685975.select
Fritsch A, Meyer M, Blaustein RO, Trujillo ME, Kauh E, Roessig L, Boettcher M, Becker C. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. Clin Pharmacokinet. 2024 Jun;63(6):751-771. doi: 10.1007/s40262-024-01384-1. Epub 2024 Jun 25. Review. PubMed PMID: 38916717; PubMed Central PMCID: PMC11222283.select
Schmitt W, Diedrich C, Hamza TH, Meyer M, Eissing T, Breitenstein S, Rossano JW, Lipshultz SE. NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure. Pediatr Cardiol. 2025 Mar;46(3):694-703. doi: 10.1007/s00246-024-03489-7. Epub 2024 May 9. PubMed PMID: 38722325; PubMed Central PMCID: PMC11842395.select
Frechen S, Ince I, Dallmann A, Gerisch M, Jungmann NA, Becker C, Lobmeyer M, Trujillo ME, Xu S, Burghaus R, Meyer M. Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):79-92. doi: 10.1002/psp4.13059. Epub 2023 Oct 12. PubMed PMID: 37794724; PubMed Central PMCID: PMC10787200.select
Ruehs H, Solms A, Frei M, Becker C, Trujillo ME, Garmann D, Meyer M. Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches. Clin Pharmacokinet. 2023 Nov;62(11):1639-1648. doi: 10.1007/s40262-023-01282-y. Epub 2023 Sep 6. PubMed PMID: 37672197; PubMed Central PMCID: PMC10581916.select
Rao VN, Cyr DD, Wruck LM, Sanders G, Hofmann P, Rössig L, Siedentop H, Evers T, Meyer M, Paraschin K, Nkulikiyinka R, Parikh K, Felker GM. Electronic health record characterization and outcomes of heart failure with preserved ejection fraction. Am Heart J. 2023 Sep;263:1-14. doi: 10.1016/j.ahj.2023.04.013. Epub 2023 Apr 26. PubMed PMID: 37116604.select
Willmann S, Keller AK, Meyer M, van der Mey D, Wirsching G, Zhang Y, Drenth HJ, Keunecke A, Vendel E, Saleh S. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatr Pulmonol. 2023 Mar;58(3):908-917. doi: 10.1002/ppul.26277. Epub 2022 Dec 28. PubMed PMID: 36507572.select
Trujillo ME, Arrington L, Patel Y, Passarell J, Wenning L, Blaustein RO, Armstrong PW, Meyer M, Becker C, Gheyas F. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. Clin Pharmacol Ther. 2022 Nov;112(5):1061-1069. doi: 10.1002/cpt.2712. Epub 2022 Aug 13. PubMed PMID: 35841202.select
Ruehs H, Klein D, Frei M, Grevel J, Austin R, Becker C, Roessig L, Pieske B, Garmann D, Meyer M. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clin Pharmacokinet. 2021 Nov;60(11):1407-1421. doi: 10.1007/s40262-021-01024-y. Epub 2021 Jun 4. PubMed PMID: 34086190; PubMed Central PMCID: PMC8585847.select
Ince I, Dallmann A, Frechen S, Coboeken K, Niederalt C, Wendl T, Block M, Meyer M, Eissing T, Burghaus R, Lippert J, Willmann S, Schlender JF. Predictive Performance of Physiology-Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small-Molecule Compounds in Children. J Clin Pharmacol. 2021 Jun;61 Suppl 1(Suppl 1):S70-S82. doi: 10.1002/jcph.1869. PubMed PMID: 34185905; PubMed Central PMCID: PMC8361729.select
Schmitt W, Rühs H, Burghaus R, Diedrich C, Duwal S, Eissing T, Garmann D, Meyer M, Ploeger B, Lippert J. NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. PubMed PMID: 33630302; PubMed Central PMCID: PMC8360001.select
Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, Hempel G. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clin Pharmacokinet. 2017 Dec;56(12):1525-1541. doi: 10.1007/s40262-017-0538-0. PubMed PMID: 28391404.select
Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clin Pharmacokinet. 2017 Nov;56(11):1303-1330. doi: 10.1007/s40262-017-0539-z. Review. PubMed PMID: 28401479.select
Radke C, Horn D, Lanckohr C, Ellger B, Meyer M, Eissing T, Hempel G. Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients. Clin Pharmacokinet. 2017 Jul;56(7):759-779. doi: 10.1007/s40262-016-0475-3. PubMed PMID: 28039606.select
Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. doi: 10.1007/s40262-016-0422-3. PubMed PMID: 27351180; PubMed Central PMCID: PMC5107207.select
Somani AA, Thelen K, Zheng S, Trame MN, Coboeken K, Meyer M, Schnizler K, Ince I, Willmann S, Schmidt S. Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds. Br J Clin Pharmacol. 2016 Jan;81(1):137-47. doi: 10.1111/bcp.12752. Epub 2015 Oct 30. PubMed PMID: 26302359; PubMed Central PMCID: PMC4693582.select
Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos. 2012 May;40(5):892-901. doi: 10.1124/dmd.111.043174. Epub 2012 Jan 31. PubMed PMID: 22293118.select
Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund HU, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol. 2011;2:4. doi: 10.3389/fphys.2011.00004. eCollection 2011. PubMed PMID: 21483730; PubMed Central PMCID: PMC3070480.select
Saleem M, Meyer MC, Breitenstein D, Galla HJ. Calcium ions as „miscibility switch“: colocalization of surfactant protein B with anionic lipids under absolute calcium free conditions. Biophys J. 2009 Jul 22;97(2):500-8. doi: 10.1016/j.bpj.2009.05.011. PubMed PMID: 19619464; PubMed Central PMCID: PMC2711324.select
Saleem M, Meyer MC, Breitenstein D, Galla HJ. The surfactant peptide KL4 in lipid monolayers: phase behavior, topography, and chemical distribution. J Biol Chem. 2008 Feb 22;283(8):5195-207. doi: 10.1074/jbc.M705944200. Epub 2007 Dec 19. PubMed PMID: 18093983.select
Na Nakorn P, Meyer MC, Flach CR, Mendelsohn R, Galla HJ. Surfactant protein C and lung function: new insights into the role of alpha-helical length and palmitoylation. Eur Biophys J. 2007 Apr;36(4-5):477-89. doi: 10.1007/s00249-006-0102-6. Epub 2006 Oct 19. PubMed PMID: 17051367.select
Altrup U, Häder M, Cáceres JL, Malcharek S, Meyer M, Galla HJ. Epileptogenic drugs in a model nervous system: electrophysiological effects and incorporation into a phospholipid layer. Brain Res. 2006 Nov 29;1122(1):65-77. doi: 10.1016/j.brainres.2006.09.021. Epub 2006 Oct 17. PubMed PMID: 17049497.select
Menke M, Ross M, Gerke V, Steinem C. The molecular arrangement of membrane-bound annexin A2-S100A10 tetramer as revealed by scanning force microscopy. Chembiochem. 2004 Jul 5;5(7):1003-6. doi: 10.1002/cbic.200400004. PubMed PMID: 15239061.select
Ross M, Gerke V, Steinem C. Membrane composition affects the reversibility of annexin A2t binding to solid supported membranes: a QCM study. Biochemistry. 2003 Mar 18;42(10):3131-41. doi: 10.1021/bi027069z. PubMed PMID: 12627981.select
Kastl K, Ross M, Gerke V, Steinem C. Kinetics and thermodynamics of annexin A1 binding to solid-supported membranes: a QCM study. Biochemistry. 2002 Aug 6;41(31):10087-94. doi: 10.1021/bi025951z. PubMed PMID: 12146973.select
Ross M, Krol S, Janshoff A, Galla HJ. Kinetics of phospholipid insertion into monolayers containing the lung surfactant proteins SP-B or SP-C. Eur Biophys J. 2002 Mar;31(1):52-61. doi: 10.1007/s002490100181. PubMed PMID: 12046897.